Form 4 for EW Edwards Lifesciences
Accepted 2026-02-13 00:00:00 ET · period of report 2026-02-12 · accession 0001225208-26-001893 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-13 | 2026-02-12 | EW | Zovighian Bernard J | CEO, Dir | S - Sale+OE | $76.67 | -22.4K | 103.8K | -18% | -$1.72M |
| DI | 2026-02-13 | 2026-02-13 | EW | Zovighian Bernard J | CEO, Dir | G - Gift | $0.00 | +2,920 | 11.5K | +34% | $0 |
| D | 2026-02-13 | 2026-02-12 | EW | Zovighian Bernard J | CEO, Dir | M - OptEx | $59.26 | +25.4K | 106.3K | +31% | +$1.50M |
| D | 2026-02-13 | 2026-02-13 | EW | Zovighian Bernard J | CEO, Dir | G - Gift | $0.00 | -2,920 | 81.0K | -3% | $0 |
| D | 2026-02-13 | 2026-02-12 | EW | Zovighian Bernard J | CEO, Dir | M - OptEx | $0.00 | -25.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-12 | S | D | 19,898 | $76.61 | 83,896 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $76.080 to $77.075 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2026-02-13 | G | A | 2,920 | $0.00 | 11,516.55 | I | — | — | |
| 3 | Common | Common Stock | 2026-02-12 | S | D | 2,532 | $77.13 | 103,794 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $77.080 to $77.225 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2026-02-12 | M | A | 25,350 | $59.26 | 106,326 | D By Trust | — | — | |
| 5 | Common | Common Stock | 2026-02-13 | G | D | 2,920 | $0.00 | 80,976 | D | — | — | |
| 6 | Derivative | Employee Stock Option (Right to Acquire) | 2026-02-12 | M | D | 25,350 | $0.00 | 0 | D | $59.26 · — to 2026-05-07 | 25,350 Common Stock | (F4) These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |